JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB21286

Anti-Collagen I 抗体

Anti-Collagen I antibody

4

(16 Reviews)

|

(292 Publications)

Anti-Collagen I antibody (ab21286) is a rabbit polyclonal antibody detecting Collagen I in Western Blot, IHC-P, IHC-Fr, ICC/IF, ELISA. Suitable for Mouse.

- Over 230 publications
- Trusted since 2005

別名を表示する

Cola1, Col1a1, Collagen alpha-1(I) chain, Alpha-1 type I collagen

8 Images
Immunocytochemistry/ Immunofluorescence - Anti-Collagen I antibody (AB21286)
  • ICC/IF

CiteAb

Immunocytochemistry/ Immunofluorescence - Anti-Collagen I antibody (AB21286)

Collagen I immunocytochemistry-immunofluorescence using Anti-Collagen I antibody ab21286. Publication image and figure legend from Tan, T., Hu, H., et al. 2019, Nature Communications PubMed 31346166.

Efficient remodeling of TSM by D-bLP-mediated photothermal effects. At 12 -h post injection of D-bLP, one tumor was exposed to 808 -nm laser at 2.5 W cm−2 for 5 min, and the other one was not irradiated. These tumor tissues were collected at 4 h after laser irradiation for further measurements (a-e). a Variation of CAF and TAM populations in tumor with and without laser irradiation, scale bar, 100 µm. CAF were characterized by αSMA+/CD31- cells, which was denoted as cells with green signals, excluding red signals; TAM were presented as cells with green signals (F4/80). b Expression of collagen I and fibronectin in tumor with and without laser irradiation (green signals), scale bar, 100 µm. c Proportion of 4T1-GFP cancer cells (green signals) in tumor with and without laser irradiation, scale bar, 500 µm. d Histological examinations of tumors with and without laser irradiation by hematoxylin and eosin (H&E) staining, scale bar, 100 µm. Black arrow, karyopyknosis; red arrow, hemorrhage. e The quantified results of CAF, TAM, collagen I, fibronectin, and 4T1-GFP cancer cells in tumor with and without laser irradiation (n = 3). f Quantified variations of CAF, TAM, collagen I, fibronectin, and 4T1-GFP cancer cells in the D-bLP + laser-treated group at different time points after laser irradiation (n = 3). The data are means ± SD, *p < < 0.05, **p < < 0.01, n.s. not significant (ANOVA and two-tailed Student t test)

Immunohistochemistry (Frozen sections) - Anti-Collagen I antibody (AB21286)
  • IHC-Fr

CiteAb

Immunohistochemistry (Frozen sections) - Anti-Collagen I antibody (AB21286)

Collagen I immunohistochemistry (frozen sections) using Anti-Collagen I antibody ab21286. Publication image and figure legend from Patra, D., DeLassus, E., et al., 2018, Biology Open, 7 PubMed 29437042.

Molecular analysis of embryonic bone development. IF for Runx2 (red; A-F), Col II THD (green, A-C), and Col I (red, J-L) in E15.5 femora. D-F are higher magnification images of A-C (magnified region outlined in A-C; shown without signals from Col II). ISH analysis for Sp7 (Osx) in E15.5 femora (G-I). Scale bars : (A-C,J-L) 100 μm; (D-F) 10 μm; (G-I) 250 μm.

Immunohistochemistry (Frozen sections) - Anti-Collagen I antibody (AB21286)
  • IHC-Fr

CiteAb

Immunohistochemistry (Frozen sections) - Anti-Collagen I antibody (AB21286)

Immunohistochemistry-immunofluorescence using Anti-Collagen I antibody ab21286. Publication image and figure legend from Kamata, M., Amano, H., et al. 2019, PLoS One, PubMed 30818366.

Tubulointerstitial fibrosis is less severe in BLT1-/- mice following UUO.(A) Representative images of kidney cortex from WT and BLT1-/- mice immunostained with an anti-type I collagen antibody. Scale bars = 50 μm. (B) Temporal changes in the area of immunoreactive collagen within tubulointerstitial spaces (expressed as % total area, excluding glomeruli and large vessels). Data are expressed as the mean ± SEM (n = 4 mice/group). *P<0.05 and **P<0.01, vs. WT. Expression of Col1a1 mRNA (C) and Col3a1 (D) mRNA in WT and BLT1-/- mice kidneys, as measured by real-time PCR. Data are expressed as the mean ± SEM (WT; Day 0 : n = 8, Day 1, 3, 5, 7 : n = 16 BLT1; Day 0 : n = 8, Day 1, 3, 5 : n = 16, Day 7 : n = 14 mice per group) *P<0.05 and **P<0.01, vs. WT. (D) Representative images showing S100A4 staining in WT and BLT1-/- kidneys after UUO. Scale bars = 100 μm. (E) Changes in the number of S100A4-positive cells in WT UUO and BLT1-/- UUO kidneys. (F) The number of S100A4-positive cells was significantly lower in BLT1-/- UUO kidneys. Data are expressed as the mean ± SEM (n = 4 mice/group). (G, H) Expression of mRNA encoding S100A4 (G) and αSMA (H) in UUO kidneys, as measured by real-time PCR. Data are expressed as the mean ± SEM (WT; Day 0 : n = 7, Day 1 : n = 12, Day 3, 5, 7 : n = 18 BLT1; Day 0 : n = 7, Day 1 : n = 12, Day 3, 5 : n = 16, Day 7 : n = 18 mice per group). *P<0.05 and **P<0.01, vs. WT. H, I) Expression of mRNA encoding TGF-β (I) and FGF-2 (J) in mouse kidneys after induction of UUO. Data are expressed as the mean ± SEM (TGF-β : WT; Day 0 : n = 8, Day 1 : n = 16, Day 3, 5, 7 : n = 20 BLT1; Day 0 : n = 8, Day 1 : n = 14, Day 3, 5 : n = 20, Day7 : n = 18 mice per group. FGF-2 : WT; Day 0 : n = 8, Day 1, 3, 5, 7 : n = 16 BLT1; Day 0 : n = 8, Day 1, 3, 5, 7 : n = 16 mice per group). *P<0.05 and **P<0.01, vs. WT mice.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Collagen I antibody (AB21286)
  • IHC-P

CiteAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Collagen I antibody (AB21286)

Collagen I Immunohistochemistry-paraffin-immunofluorescence using Anti-Collagen I antibody ab21286. Publication image and figure legend from Fransén-Pettersson, N., Duarte, N., et al., 2016, PLoS One, PubMed 27441847.

The N-IF mouse develops liver fibrosis. Representative liver sections from 11 weeks old N-IF and 24αβNOD control mice stained with Sirius red. Representative images from two independent experiments with a total of six mice are shown. Scale bars are 500 μm in the overview images (left) and 100 μm in the enlarged images (right) (A). Immunofluorescence staining showing (B) collagen I (red), CD45 (cyan) and DAPI (blue); (C) MMP9 (green) and DAPI (blue) and; (D) ASMA (red) and DAPI (blue), in 12 weeks old N-IF and 24αβNOD control mouse livers. Representative images from two independent experiments with a total of six mice are shown. Scale bars are 100 μm. (E) Hydroxyproline content per mg liver tissue from N-IF and 24αβNOD mice (n = 6). Data are pooled from two independent experiments and shown as mean ± SEM ***p<0.001 by unpaired t-test.

Immunohistochemistry (Frozen sections) - Anti-Collagen I antibody (AB21286)
  • IHC-Fr

CiteAb

Immunohistochemistry (Frozen sections) - Anti-Collagen I antibody (AB21286)

immunohistochemistry-immunofluorescence using Anti-Collagen I antibody ab21286. Publication image and figure legend from Li, C., Zhen, G., et al., 2016, Nat Commun, PubMed 27126736.

Activation of RhoA promotes CTGF-VEGF complex formation in ECM, whereas inactivation of RhoA induces MMP3-mediated CTGF cleavage and VEGF release.(a-d) Immunofluorescence analysis of the binding of VEGF to ECM in different MSC cultures. MSCs were incubated with the indicated treatments for 7 days. Immunofluorescence staining was performed on non-permeabilized cells using antibodies against CTGF (a), fibronectin (b), collagen I (c) or VEGF (d). (e,f) MSCs were transfected with siRNA-control or siRNA-CTGF, then cultured with the indicated medium for 6 days. Western blot (WB) analysis of the cell lysates was performed using antibodies against CTGF and β-actin (e). Immunofluorescence staining was performed on non-permeabilized cells using antibodies against CTGF or VEGF (f). (g-j) WB and co-immunoprecipitation (IP) analyses of VEGF and CTGF in the overlay media of MSCs with different treatment. MSCs were incubated with the indicated treatments for 7 days. Overlay media : M1, M2, M3 and M4 were collected, respectively. Western blotting analysis of the overlay media was performed using antibodies against CTGF (g), MMP3 (h) and VEGF (i). Overlay media were subjected to IP assays using antibody against VEGF, the VEGF-associated CTGF was detected by western blotting with antibody against CTGF (j). (k,l) WB analysis of VEGF and CTGF in the ECMs of the cultured MSCs with different treatment. MSCs were incubated with the indicated treatment for 7 days. ECMs : E1, E2, E3 and E4 were collected. Western blotting analysis of the ECMs was performed using antibodies against CTGF (k) and VEGF (l). (m-o) WB and co-IP analysis of VEGF and CTGF in the overlay media of MSCs transfected with empty vector (EV) or L63RhoA. In the aliquots of the overlay medium collected from the cells overexpressed L63RhoA, 50 or 100 ng ml−1 rMMP3 was added and the reactions were maintained at 37 °C for 2 h. Overlay media were subjected to immunoprecipitation assays using antibody against VEGF, the VEGF-associated CTGF was detected by western blotting with antibody against CTGF (m). Western blotting analysis of the overlay media was performed using antibodies against CTGF (n) and MMP3 (o). Scale bars, 50 μm. Data are representative of three independent experiments.

Western blot - Anti-Collagen I antibody (AB21286)
  • WB

CiteAb

Western blot - Anti-Collagen I antibody (AB21286)

-Collagen I western Blotting using Anti-Collagen I antibody ab21286. Publication image and figure legend from Sun, F. & Hu, K. 2016,Dis Markers, PubMed 26839446.

PAI-1 knockdown inhibits the TGF-β-promoted EMT in LA-4 cells. (a) PAI-1 mRNA level in LA-4 cells which were transfected with 20 or 40 nM PAI-1-specific siRNA (siRNA-PAI-1) or with control siRNA (siRNA-Con) for 12 hours. (b) Western blot analysis of PAI-1 in LA-4 cells which were transfected with 20 or 40 nM siRNA-PAI-1 or with siRNA-Con for 24 hours. (c) Western blot analysis of PAI-1, E-cadherin, and Collagen I in LA-4 cells which were transfected with 20 or 40 nM siRNA-PAI-1 or with siRNA-Con and were treated with 5 ng/mL TGF-β for 24 hours. (d) and (e) Relative levels of PAI-1 (d) or E-cadherin and Collagen I (e) in the siRNA-PAI-transfected and the TGF-β-treated LA-4 cells. All results were shown as values ± SE for three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, or ns : no significance.

false

Western blot - Anti-Collagen I antibody (AB21286)
  • WB

CiteAb

Western blot - Anti-Collagen I antibody (AB21286)

Collagen I western Blotting using Anti-Collagen I antibody ab21286. Duan, R., Hong, C. G., et al., 2024 BMC Pulmonary Medicine, PubMed 38178092.

Administration of OM-MSCs downregulates the expression of fibrotic factors from BLM-induced pulmonary fibrosis. (A-B) Representative images and quantification of COL1A1 staining of lung tissues from control mice or BLM-induced mice with or without OM-MSCs treatment. Scale bar : 200 mm. n = 4 per group. (C-D) Representative images and quantification of ACTA2 staining of lung tissues from control mice or BLM-induced mice with or without OM-MSCs treatment. Scale bar : 200 mm. n = 4 per group. (E-F) Representative images and quantification of MMP13 staining of lung tissues from control mice or BLM-induced mice with or without OM-MSCs treatment. Scale bar : 200 mm. n = 4 per group. (G) Measurement of hydroxyproline depositions in lung tissue of control mice or BLM-induced mice with or without OM-MSC treatment. n = 4 per group. (H-K) Representative western blot analysis and quantification of COL1A1, MMP13, ACTA2. n = 3 per group. Full-length blots/gels are presented in Supplementary file 2. (L-N) QPCR analysis of Col1a1, Mmp13, Acta2. n = 6 per group

false

Western blot - Anti-Collagen I antibody (AB21286)
  • WB

CiteAb

Western blot - Anti-Collagen I antibody (AB21286)

Western Blotting using Anti-Collagen I antibody, ab21286. Publication image from Mori, M. et al., 2016, Nat Commun, 27527664. Legend direct from paper.

Mkx promotes the differentiation of mesenchymal stem cells to ligament cells.(a) Images of C3H10T1/2 cells induced by Venus (C3H10T1/2-V or Venus) and Venus-Mkx (C3H10T1/2-VM or Venus-Mkx) in plate culture. Scale bars, 500 µm (top); 100 µm (bottom). (b–e) Quantitative real-time reverse transcription PCR (qRT–PCR) analyses of the expression of ligament, cartilage, bone and fat-related genes in C3H10T1/2-V and C3H10T1/2-VM cells. mRNA levels in C3H10T1/2-V cells were normalized to 1. Error bars represent s.e.m. *P<0.05, **P<0.01, ***P<0.001. Statistical differences were assessed with Student's t-test. (f) Western blot analyses of C3H10T1/2-V and C3H10T1/2-VM cells for lineage markers.

false

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

IgG

キャリアフリー

No

交差種

Mouse

アプリケーション

ELISA, WB, RIA, ICC/IF

applications

免疫原

Native Full Length Protein corresponding to Mouse Col1a1.

P11087

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "RIA" : {"fullname" : "Radioimmunoassay", "shortname":"RIA"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCFr" : {"fullname" : "Immunohistochemistry (Frozen sections)", "shortname":"IHC-Fr"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "ELISA-species-checked": "guaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "<p></p>", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "RIA-species-checked": "guaranteed", "RIA-species-dilution-info": "", "RIA-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IHCFr-species-checked": "notRecommended", "IHCFr-species-dilution-info": "", "IHCFr-species-notes": "<p></p>" } } }

製品の詳細

Anti-Collagen I antibody (ab21286) is a rabbit polyclonal antibody and is validated for use in ELISA, ICC/IF, RIA, WB in mouse samples.

Anti-Collagen I antibody (ab21286) has been cited over 230 times in peer reviewed journals and is trusted by the scientific community.

Abcam's high quality validation processes ensure Anti-Collagen I antibody (ab21286) has high sensitivity and specificity.

Anti-Collagen I (Cola1; Collagen type I) antibody (ab21286) has 16 independent reviews from customers.

Anti-Collagen I antibody (ab21286) specifically detects Collagen I (UniProt ID: P02452; Molecular weight: ~140kDa) and is sold in 100 µL selling sizes.

Collagen I, the most abundant collagen type in the human body, plays a significant role in oncology. It is a major component of the extracellular matrix (ECM) and contributes to the structural integrity of tissues. In cancer, Collagen I can influence tumor progression by promoting tumor cell proliferation, invasion, and metastasis through interactions with various cell surface receptors and signaling pathways.

出荷温度及び保存条件

精製に関する特記事項
Purified by Ion exchange chromatography (DEAE-Trisacryl).
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Collagen type I also called collagen I is a structural protein expressed mainly in connective tissues such as skin tendon bone and ligaments. It serves as an important component in providing mechanical strength and integrity to these tissues. Collagen I is a fibrillar collagen known for its triple-helix structure composed of two alpha-1 chains and one alpha-2 chain and has a molecular mass of approximately 300 kDa. Researchers often employ collagen western blot and collagen ELISA techniques for its detection. Collagen suppliers offer various collagen antibodies used in these assays to study its distribution and function.
Biological function summary

Collagen type I plays a central role in maintaining the extracellular matrix and supporting cellular environments. It interacts with other matrix proteins and cells forming complexes that help in tissue development and repair. Type I collagen is especially important in bone matrix working alongside minerals like hydroxyapatite to provide rigidity and support. Anti-collagen antibodies aid in studying its biological functions and interactions which are critical to understanding tissue dynamics.

Pathways

Collagen type I interacts with multiple signaling cascades involved in tissue remodeling and repair. It is a significant player in the TGF-β pathway which regulates fibrosis and wound healing processes. In these pathways proteins such as fibronectin and integrins work in concert with collagen type I to orchestrate cellular responses to damage. Researchers often examine its role in these pathways to uncover therapeutic possibilities for disease interventions.

Collagen type I has strong connections to conditions like osteogenesis imperfecta and fibrosis. Mutations or irregularities in collagen I production can lead to osteogenesis imperfecta a genetic disorder characterized by brittle bones. In fibrosis excessive collagen deposition disrupts normal tissue architecture contributing to organ dysfunction. In both conditions type I collagen interacts with other proteins like matrix metalloproteinases which modulate its breakdown and remodeling highlighting its importance in disease pathology.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Type I collagen is a member of group I collagen (fibrillar forming collagen).
See full target information Col1a1

文献 (292)

Recent publications for all applications. Explore the full list and refine your search

JCI insight 10: PubMed40985890

2025

Nf2/FGFR1/AKT axis directs cranial neural crest-derived skull morphogenesis via collagen synthesis and trafficking.

Applications

Unspecified application

Species

Unspecified reactive species

Yuping Huang,Junguang Liao,Panpan Shen,Yiliang He,Fuju Sun,Qi Zhang,Changlin Zheng,Xingen Zhang,Haibo Li,Guiqian Chen

Science advances 11:eadv2628 PubMed40668913

2025

Multicellular muscle-tendon bioprinting of mechanically optimized musculoskeletal bioactuators with enhanced force transmission.

Applications

Unspecified application

Species

Unspecified reactive species

Miriam Filippi,Diana Mock,Judith Fuentes,Mike Y Michelis,Aiste Balciunaite,Pablo Paniagua,Raoul Hopf,Adina Barteld,Selina Eng,Asia Badolato,Jess Snedeker,Maria Guix,Samuel Sanchez,Robert K Katzschmann

Cell death & disease 16:505 PubMed40634289

2025

Failure to resolve inflammation contributes to juvenile onset cardiac damage in a mouse model of Duchenne muscular dystrophy.

Applications

Unspecified application

Species

Unspecified reactive species

James S Novak,Amy Lischin,Prech Uapinyoying,Ravi Hindupur,Young Jae Moon,Surajit Bhattacharya,Sarah Tiufekchiev-Grieco,Victoria Barone,Davi A G Mázala,Iteoluwakishi H Gamu,Gabriela Walters,Jyoti K Jaiswal

The Journal of clinical investigation 135: PubMed40540411

2025

Angiopoietin-like protein 2 mediates vasculopathy-driven fibrogenesis in a mouse model of systemic sclerosis.

Applications

Unspecified application

Species

Unspecified reactive species

Dyuti Saha,Ravi Kiran Annadorai,Sujaya Thannimangalath,Neha P Shroff,Sunny Kataria,Binita Dam,Abhik Dutta,Akshay Hegde,Ankita Hiwale,Venkatesh Ravula,Shagnik Saha,Lekshmi Minikumari Rahulan,Neha Nigam,Neha Singh,Vikas Agarwal,Praveen K Vemula,Colin Jamora

Calcified tissue international 116:81 PubMed40478277

2025

Mineral Content and Extracellular Matrix Protein Expression in Mouse Growth Plates During Epiphyseal Fusion: An Observational Study.

Applications

Unspecified application

Species

Unspecified reactive species

Xinhang Yu,Megumi Nakamura,Miyuki Mayanagi,Itaru Mizoguchi,Yasuyuki Sasano

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 39:e70666 PubMed40471098

2025

METTL3 Modulates Radiation-Induced Cardiac Fibrosis via the Akt/mTOR Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Shunsong Qiao,Chao Tang,Jingjing Zhu,Yu Feng,Li Xiang,Jing Zhu,Xiaosong Gu

Micromachines 16: PubMed40428678

2025

Low-Temperature Electrospinning-Fabricated Three-Dimensional Nanofiber Scaffolds for Skin Substitutes.

Applications

Unspecified application

Species

Unspecified reactive species

Qiqi Dai,Huazhen Liu,Wenbin Sun,Yi Zhang,Weihuang Cai,Chunxiang Lu,Kaidi Luo,Yuanyuan Liu,Yeping Wang

Cells 14: PubMed40422230

2025

Taurine Prevents Impairments in Skin Barrier Function and Dermal Collagen Synthesis Triggered by Sleep Deprivation-Induced Estrogen Circadian Rhythm Disruption.

Applications

Unspecified application

Species

Unspecified reactive species

Qi Shao,Zhaoyang Wang,Yifang Li,Xun Tang,Ziyi Li,Huan Xia,Qihong Wu,Ruxue Chang,Chunna Wu,Tao Meng,Yufei Fan,Yadong Huang,Yan Yang

International journal of molecular sciences 26: PubMed40243849

2025

Inhibiting Myostatin Expression by the Antisense Oligonucleotides Improves Muscle Wasting in a Chronic Kidney Disease Mouse Model.

Applications

Unspecified application

Species

Unspecified reactive species

Arju Akhter,Abdullah Md Sheikh,Jun Yoshino,Takeshi Kanda,Atsushi Nagai,Masafumi Matsuo,Shozo Yano

Theranostics 15:4526-4549 PubMed40225577

2025

Targeting USP11 counteracts -associated interstitial lung disease in hiPSCs-derived alveolar organoids and in vivo models.

Applications

Unspecified application

Species

Unspecified reactive species

Janardhan Keshav Karapurkar,Sripriya Rajkumar,Ji-Hye Jung,Ji-Young Kim,Girish Birappa,D A Ayush Gowda,Jencia Carminha Colaco,Bharathi Suresh,Jung-Yun Choi,Sang Hyeon Woo,Won-Jun Jo,Jong-Hee Lee,Kye-Seong Kim,Seok-Ho Hong,Suresh Ramakrishna
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com